Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14001974 | 0.80 | PAK4 (0.40) | SMN1; SMN2NPSR1PAK4ALDH1A1LMNA | |
| SCHEMBL1085819 | 0.78 | NPSR1 (0.33) | SMN1; SMN2NPSR1PAK4ALDH1A1LMNA | |
| SCHEMBL15742226 | 0.77 | NPSR1 (0.36) | SMN1; SMN2NPSR1PAK4ALDH1A1LMNA | |
| SCHEMBL1085685 | 0.76 | KDM4E (0.34) | SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL15742361 | 0.72 | LMNA (0.33) | SMN1; SMN2NPSR1ALDH1A1LMNANPC1 | |
| SCHEMBL15292260 | 0.71 | — | — | |
| SCHEMBL1357520 | 0.70 | — | — | |
| SCHEMBL23212183 | 0.70 | ALDH1A1 (0.35) | SMN1; SMN2NPSR1ALDH1A1LMNA | |
| SCHEMBL3254688 | 0.69 | RAB9A (0.33) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL3251664 | 0.69 | GAA (0.34) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195678-A | Intermediate, preparation method thereof and method for preparing 3-difluoromethyl-1-methylpyrazole-4-ethyl formate by using intermediate | 江苏七洲绿色科技研究院有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-2164831-B1 | METHOD FOR THE PRODUCTION OF N-SUBSTITUTED (3-DIHALOMETHYL-1-METHYL-PYRAZOLE-4-YL) CARBOXAMIDES | BASF SE (DE) | 2013-07-17 | — | — | EP | disclosed |
| CN-101679282-B | Process for producing N-substituted (3-dihalomethyl-1-methylpyrazol-4-yl) carboxamides | BASF SE | 2012-11-28 | — | — | CN | disclosed |
| US-8153820-B2 | Method for the production of N-substituted (3-dihalomethyl-1-methylpyrazol-4-yl) carboxamides | BASF SE (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20100256390-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256390-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100174094-A1 | Method for the Production of N-Substituted (3-Dihalomethyl-1-Methyl-Pyrazole-4-yl) Carboxamides | BASF SE (DE) | 2010-07-08 | — | — | US | disclosed |
| EP-2164831-A1 | METHOD FOR THE PRODUCTION OF N-SUBSTITUTED (3-DIHALOMETHYL-1-METHYL-PYRAZOLE-4-YL) CARBOXAMIDES | Basf Se (DE) | 2010-03-24 | — | — | EP | disclosed |
| CN-101679282-A | Process for producing N-substituted (3-dihalomethyl-1-methylpyrazol-4-yl) carboxamides | BASF SE | 2010-03-24 | — | — | CN | disclosed |
| WO-2009000442-A2 | PROCESSES FOR THE PREPARATION OF PYRAZOLES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008145740-A1 | METHOD FOR THE PRODUCTION OF N-SUBSTITUTED (3-DIHALOMETHYL-1-METHYL-PYRAZOLE-4-YL) CARBOXAMIDES | BASF SE (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256390-A1 | PROCESSES FOR THE PREPARATION OF PYRAZOLES | CYP2F1, CYP4F3, CYP4F11 | SMN1; SMN2 4819/4885NPSR1 2658/4885PAK4 1601/4885 |
| US-20100174094-A1 | Method for the Production of N-Substituted (3-Dihalomethyl-1-Methyl-Pyrazole-4-yl) Carboxamides | CBR3, CBR1, CYC1 | SMN1; SMN2 3019/4885NPSR1 1894/4885PAK4 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.